PPV and cataract surgery significantly improve VA

Article

Extensive pars plana vitrectomy and cataract extraction can significantly improve visual acuity in juvenile idiopathic arthritis patients suffering from severe ocular complications of uveitis.

Extensive pars plana vitrectomy (PPV) and cataract extraction can significantly improve visual acuity (VA) in juvenile idiopathic arthritis patients suffering from severe ocular complications of uveitis.

According to a study published in Ophthalmologica, instead of a complete lensectomy, 11 eyes of 7 patients underwent complete vitrectomy and peeling of the inner limiting membrane. Patients were included in the study if they had anteroposterior segment involvement, hypotony, inflammation control of less than 3 months, compliance issues, or rapidly progressive disease; phacoemulsification was allowed if the patient was more than 6 years old and had been inflammation-free for more than 3 months.

The researchers found that VA improved from a logMAR of 1.48 to 0.37 at 6 months and 0.20 at 12 months. No flare-up was observed within the first 6 months. Between 7 and 19 months 5 eyes developed inflammation, and at a median of 16 months glaucoma developed in 5 eyes. None of the patients in the study developed cystoid macular oedema.

To read an abstract of the study, click here.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.